Press-release for stocks for EBS

Prices are updated after-hours

symbols : EBS source : Www.biospace.com

save search

Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results
Published: 2023-08-21 (Crawled : 12:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -56.54% | O: 0.0% H: 0.0% C: -4.23%
SNGX | $0.408 -5.34% -5.64% 620K

Health Technology

| -8.95% | O: 6.6% H: 0.0% C: -5.19%
financial results

Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
Published: 2023-02-15 (Crawled : 10:00) - biospace.com/
MS | News | $92.09 1.58% 0.01% 7.3M

Finance

| -8.42% | O: -1.04% H: 1.46% C: 1.33%
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -83.71% | O: 5.58% H: 6.75% C: 6.57%
acquire travel

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Published: 2023-02-15 (Crawled : 09:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -83.71% | O: 5.58% H: 6.75% C: 6.57%
travel health

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
Published: 2023-02-06 (Crawled : 01:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -84.54% | O: -1.15% H: 1.16% C: -0.87%
conference financial results

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
Published: 2022-12-06 (Crawled : 15:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -81.68% | O: 2.04% H: 2.08% C: 1.33%
narcan fda drug spray application review

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
Published: 2022-11-01 (Crawled : 23:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -89.65% | O: 1.87% H: 1.46% C: -1.55%
candidate vaccine study chikungunya

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
Published: 2022-10-27 (Crawled : 13:20) - biospace.com/
SABS | $4.64 8.16% 7.54% 1.7K

| 455.7% | O: 7.56% H: 4.71% C: -1.14%
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -89.83% | O: 1.22% H: 0.74% C: -2.89%
partnership

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
Published: 2022-10-18 (Crawled : 11:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -89.25% | O: 2.29% H: 1.17% C: -4.91%
conference financial results

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Published: 2022-09-26 (Crawled : 21:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -89.65% | O: -0.29% H: 2.98% C: -3.41%
tembexa acquisition smallpox antiviral

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
Published: 2022-09-06 (Crawled : 11:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -90.61% | O: -0.48% H: 0.0% C: -2.58%
candidate vaccine virus study phase 1

Emergent BioSolutions to Participate in Investor Conferences - Aug 10, 2022
Published: 2022-08-10 (Crawled : 11:00) - biospace.com/
MS | News | $92.09 1.58% 0.01% 7.3M

Finance

| 6.64% | O: 1.35% H: 2.43% C: 1.55%
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -92.73% | O: 2.56% H: 0.39% C: 0.07%

Emergent BioSolutions Reports Financial Results for Second Quarter 2022
Published: 2022-08-01 (Crawled : 22:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -93.76% | O: -0.09% H: 1.88% C: -1.1%

Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
Published: 2022-07-18 (Crawled : 00:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -92.92% | O: 1.18% H: 2.4% C: -2.36%
conference results

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -92.81% | O: -6.49% H: 0.0% C: 0.0%

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M

Health Technology

| -7.51% | O: -1.05% H: 0.0% C: 0.0%
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -94.91% | O: -1.65% H: 0.0% C: 0.0%
financial results solutions report results merge

Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
Published: 2022-02-07 (Crawled : 12:30) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -95.17% | O: 2.19% H: 2.97% C: -0.15%
financial results conference results merge

Founder and Executive Chairman of Emergent BioSolutions Announces RetirementFuad El-Hibri to Retire After More Than 20 Years
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -95.55% | O: 1.84% H: 0.0% C: 0.0%
ces air merge

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
Published: 2022-01-10 (Crawled : 13:30) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology

| -95.53% | O: -0.23% H: 4.29% C: 4.15%
SNGX | $0.408 -5.34% -5.64% 620K

Health Technology

| -41.01% | O: -2.45% H: 0.28% C: -1.92%

Emergent BioSolutions is to Participate in Investor Conferences
Published: 2022-01-03 (Crawled : 13:30) - biospace.com/
EBS | News | $2.16 5.88% 0.0% 1.4M

Health Technology